UpHealth Group (GRQ) Fair Value & Analysis
Healthcare · SG · Market cap 19.4M SGD
Fair value as of: Aug 9, 2026
From 3 valuation models · updated today
Share price +17.8% over the past month.
A solid business, screening 189% undervalued on our models.
What matters now
- The price is below even our cautious bear case (0.2900 SGD). The market is more pessimistic than our downside scenario.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid quality (60/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (0.2900 SGD to 0.5500 SGD) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 9, 2026.
How to read this chart
60‑month range 0.1180 SGD – 0.4152 SGD · fair‑value band 0.2900 SGD – 0.5500 SGD · the 0.1520 SGD price screens below the 0.4400 SGD fair value. Dashed = 300-day average. As of Aug 9, 2026.
Analysis
UpHealth Group (GRQ) currently trades at 0.1520 SGD, while our model-based Fair Value estimate is 0.4400 SGD, implying the stock looks roughly 189.5% undervalued today. The Quality Score stands at 60/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Trailing-twelve-month revenue stands at 31.0M SGD. Revenue declined 18.4% year over year. It earns a return on equity of -2.3%. Net debt stands at 3.6M SGD. Fundamentals as of Aug 9, 2026
Our scenario range runs from 0.2900 SGD (bear case) to 0.5500 SGD (bull case); at 0.1520 SGD, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 24% below its 52-week high and 52% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at 189%, GRQ screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 3 models by family
Widest divergence: Asset-Based (0.3000 SGD) versus Dividend Discount (0.1400 SGD). Highest evidence: Gordon GGM (70).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 9, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 75 · Market factors (momentum, volatility) 43
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
UpHealth Group Limited operates in the medical business in Russia. The company offers cancer diagnostics and treatment, and antitumor and palliative treatment services through oncology clinics under the Euroonco brand. The company was formerly known as Don Agro International Limited and changed its name to UpHealth Group Limited in January 2026.
Full company description
UpHealth Group Limited operates in the medical business in Russia. The company offers cancer diagnostics and treatment, and antitumor and palliative treatment services through oncology clinics under the Euroonco brand. The company was formerly known as Don Agro International Limited and changed its name to UpHealth Group Limited in January 2026. The company was incorporated in 2018 and is based in Singapore.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
UpHealth Group reported revenue of 0 SGD in FY2025 versus 30.9M SGD in FY2021. Reported net income was −1.4M SGD in FY2025.
Watch GRQ: get an alert when its fair value changes →
Peer Group
Medical Care Facilities · 263 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 9, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $378.85 | $554.93 | +46% |
| Fresenius SE FRE | €41.73 | €32.15 | -23% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.58 SGD | 1.44 SGD | -44% |
| Tenet Healthcare Corporation THC | $194.91 | $338.05 | +73% |
| Rede D'Or São Luiz S.A RDOR3 | R$36.01 | R$47.31 | +31% |
| DaVita Inc DVA | $231.61 | $255.97 | +11% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,955 | ₹2,955 | -67% |
| Fresenius Medical Care AG FMS | $24.68 | $45.60 | +85% |
| Aier Eye Hospital Group 300015 | ¥8.68 | ¥7.67 | -12% |
Compare UpHealth Group with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is UpHealth Group (GRQ) overvalued or undervalued?
What is the fair value of GRQ?
What is the quality score of GRQ?
What is the revenue of UpHealth Group (GRQ)?
What is the net profit margin of GRQ?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track UpHealth Group and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.